The effectiveness of preoperative erythropoietin in averting allogenic blood transfusion among children undergoing scoliosis surgery

Journal of Pediatric Orthopaedics Part B

Volumn 7, Issue 3, 1998, Pages 203-209

  Vitale, Michael G ^a,b   Stazzone, Enrico J ^a   Gelijns, Annetine C ^a   Moskowitz, Alan J ^a   Roye Jr , David P ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b InCHOIR ^*  (United States)

Author keywords

Erythropoietin; Pediatric; Scoliosis; Transfusion

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREMEDICATION; PRIORITY JOURNAL; SCOLIOSIS; VIRUS TRANSMISSION;

EID: 0031927539     PISSN: 1060152X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01202412-199807000-00005     Document Type: Article

References (71)

1. Abraham PA, St. Peter WL, Redic-Kill KA, Halstenson CE. Controversies in determination of epoetin dosages. Clin Pharmacokinetics 1992;22(6):409-15.
2. Alexander SR. Pediatric uses of recombinant human erythropoietin: the outlook in 1991. Am J Kid Dis 1991;18(4S1):42-53.
3. Bellazzi R, Siviero C. Mathematical modeling of erythropoietin therapy in uremic anemia: does it improve cost-effectiveness? Haematologica 1994;79(2):154-64.
4. Bennett WM. Side effects of erythropoietin therapy. Am J Kid Dis 1991;18(4S1):84-6.
5. Biemsa DH, Van de Wiel A, Beguin Y, Kraaijenhagen RJ, Marx JJ. Erythropoietin activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. Eur J Clin Invest 1994;24(6):426-32.
6. Biesma DH, Marx JJ, Kraaijenhagen RJ, Franke W, Messinger D, Van de Wiel A. Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin. Lancet 1994;6(8919):367-70.
7. Birkmeyer JD, Goodnough LT, Aubuchon JP. The cost- effectiveness of preoperative autologous blood donation in total hip and knee replacement. Transfusion 1993;33:544-51.
8. Blanchard KL, Fandrey J, Golfiberg MA, Bunn HF. Regulation of the erythropoietin gene. Stem Cells 1993;11(1S):1-7.
9. Carson JL. Morbidity risk assessment in the surgically anemic patient. Am J Surg 1995;170(6A):32S-35S.
10. Cowell HR, Swickard JW. Autotransfusion in children's orthopaedics. J Bone Joint Surg Am 1974;56(5):908-12.
11. Dodd RY. The risk of transfusion transmitted infection. [editorial] N Engl J Med 1992;327:419-21.
12. Doolittle RF. Biotechnology: the enormous cost of success. N Engl J Med 1991;324:1360-1.
13. Erslev AJ. The discovery of erythropoietin. ASAIO J 1993;39:89-92.
14. Evans RW, Rader B, Mannien DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990;263(6):825-30.
15. Evans RW, Rader B, Manninen DL. Cooperative Multicenter EPO Clinical Trial Group: the quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990;263: 825-30.
16. Paris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg Am 1996;78(1):62-72.
17. Faulds D, Sorkin EM. Epoetin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anemia and the stimulation of erythropoiesis. Drugs 1989;38:863-99.
18. Flaharty KK, Grimm AM, Vlasses PH. Epoetin: human recombinant erythropoietin. Clinical Pharmacy 1989;8:769-82.
19. Goldberg MA. Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: preoperative strategies for avoiding allogeneic blood exposure. Am J Surg 1995;170(6A):37S-43S.
20. Goodnough LT, Price TH, Palvin CA, Friedman KD, Vogler WR, Khan N, Sacher R, Johnston M, Wissel M, Ciavarella D. Erythropoietin response to anemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haem 1994;87(4):695-9.
21. Goodnough LT, Price TH. The EPO study group: a phase III trial of recombinant human erythropoietin therapy in non-anemic orthopaedic patients subjected to aggressive autologous blood phlebotomy: dose, response, toxicity, and efficacy. Transfusion 1994; 34:66.
22. Goodnough LT, Riddell J, Verlorugge D, Marcus RE. Blood transfusion in hip fracture patients: implications for blood conservation programs. J Orthop Trauma 1993;7:47-51.
23. Goodnough LT, Rudnick S, Plice TH. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989;321:1163-8.
24. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin on red blood cell volume expansion in autologous blood donors for elective orthopaedic surgery. J Am Coll Surg 1994;179:171-6.
25. Goodnough LT, Vizmeg K, Riddell J, Soegiarso W. The discharge hematocrit as clinical indicator for blood transfusion in surgery patients. Transfus Med 1994;4:35-44.
26. Goodnough LT, Vizmeg K, Robecks R. Prevalence and classification of anemia in elective orthopaedic surgery patients: implications for blood conservation programs. Vox Sang 1992;63:90-5.
27. Goodnough LT, Vizmeg K, Verbrugge D. The impact of autologous blood ordering and blood procurement practices on allogeneic blood exposure in elective orthopaedic surgery patients. Am J Clin Pathol 1994;101:354-7.
28. Goodnough LT. Clinical application of recombinant erythropoietin in the perioperative period. Hematol Oncol Clin North Am 1994; 8(5):1011-20.
29. Goodnough LT. Toward bloodless surgery: erythropoietin therapy in the surgical setting. Semin Oncol 1992;19(3S8):19-24.
30. Harris WH, Sledge CB. Total hip and total knee replacement. N Engl J Med 1990;323:725-31.
31. Healy JC, Frankforter SA, Graves BK, Reddy RL, Beck JR. Preoperative autologous blood donation in total hip arthroplasty. Arch Pathol Lab Med 1994;118:465-70.
32. Holland PV. Transfusion transmitted infectious diseases. J Fla Med Assoc 1993;80(1):33-6.
33. Horl WH. Iron metabolism and iron substitution during erythropoietin therapy. Clin Invest 1994;72(6S):11S-15S.
34. Hoynck van Papendrecht MA, Jeekel H, Busch OR, Marquet RL. Efficacy of recombinant erythropoietin for stimulating erythropoiesis after blood loss and surgery: an experimental study in rats. Eur J Surg 1992;158(2):83-7.
35. Jelkmann W. Biology of erythropoietin. Clin Invest 1994;72(6):3-10S.
36. Jensen JD, Jensen LW, Madsen JK. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol 1994;46(4):333-7.
37. Klein HG. Allogeneic transfusion risks in the surgical patient. Am J Surg 1995;170(6A):21S-26S.
38. Kyo S, Omoto R, Hirashima K, Eguchi S, Fujita T. Effect of human recombinant erythropoietin on reduction of homologous blood transfusion in open heart surgery: a Japanese multicenter study. Circulation 1992;86(5S):413-8.
39. Lazarus JM. Update the adverse reactions to erythropoietin therapy. ASAIO J 1993;39:70-1.
40. Levin NW. Quality of life and hematocrit level. Am J Kid Dis 1992;20(1S):16-20.
41. Levine EA, Rosen AL, Gould SA. Recombinant human erythropoietin and autologous blood donations. Surgery 1988;104:365-9.
42. MacEwen GD, Bennett E, Guille JT. Autologous blood transfusions in children and young adults with low body weight undergoing spinal surgery. J Pediatr Onhop 1990;10(6):750-3.
43. Mann DC, Wilham MR, Brower EM, Nash CL. Decreasing homologous blood transfusion in spinal surgery by use of the cell saver and predeposited blood. Spine 1989;14(12):1296-1300.
44. McNamee FP, van Doorslaer E, Segaar R. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: benefits and costs of erythropoietin. In: J Technol Assess Health Care 1993;9(4):490-504.
45. Mercuriali F, Inghilleri G, Biffi E, Colotti MT, Vinci A, Scalamogna R, Zanella A. Erythropoietin treatment to increase autologous blood donation in patients with low basal hematocrit undergoing elective orthopedic surgery. Clin Invest 1994;72(6S):16-18S.
46. Mercuriali F, Zanella A, Barosi G. Use of erythropoietin to increase the volume of autologous blood donated by orthopaedic patients. Transfusion 1993;33:55-9.
47. Miller BA, Cheung XY. Mechanisms of erythropoietin signal transduction: involvement of ∼7 calcium channels. Proc Soc Exp Biol Med 1994;206(3):263-7.
48. Paganini EP. Insights into dosage delivery of erythropoietin. ASAIO J 1993;39:72-3.
49. Pierelli G, Menichella G, Scambia L, Teofili S, Iovino R, Serafini PB, Panici G, Salerno C, Rumi G, Zini G. In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplant 1994;14:23-30.
50. Rollo VJ, Hozack WJ, Rothman RH, Chao W, Eng KO. Prospective randomized evaluation of blood salvage techniques for primary total hip arthroplasty. J Arthroplasty 1995;10(4):553-9.
51. Romanowski RR, Sytkoski AJ. The molecular structure of human erythropoietin. Hematol Oncol Clin North Am 1994;8(5):885-94.
52. Rosenblum LS, Castro KG, Dooley S, Morgan M. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States, 1985 to 1990. Ann Intern Med 1994;121:786-92.
53. Rosengart TK, Helm RE, Klemperer J, Krieger KH, Isom OW. Combined aprotinin and erythropoietin use for blood conservation: results with Jehovah's Witnesses. Ann Thorac Surg 1994;58(5): 1397-403.
54. Rothstein P, Roye DP Jr, Verdisco L, Stem L. Preoperative use of erythropoietin in an adolescent Jehovah's Witness. Anesthesiology 1990;73:568-70.
55. Rothstein P, Roye DP Jr, Verdisco L. Experience with preoperative administration of erythropoietin in adolescents undergoing scoliosis surgery. Personal communication, 1997.
56. Roye DP Jr, Rothstein P, Rickert JB, Verdisco L, Farcy JP. The use of preoperative erythropoietin in scoliosis surgery. Spine 1992;17(6S):204-5.
57. Sawyer ST, Penta K. Erythropoietin cell biology. Hematol Oncol Clin North Am 1994;8(5):895-911.
58. Semenza GL. Regulation of erythropoietin production. Hematol Oncol Clin North Am 1994;8(5):862-84.
59. Setoguchi Y, Danel C, Crystal RG. Stimulation of erythropoxesis by in vivo gene therapy: physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector. Blood 1994;84(9):2946-53.
60. Shenot ML, MacEwen GD. Autotransfusion in adolescents undergoing spinal fusion. Jeff Orthop J 1979;9:43-8.
61. Simpson MB, Georgopoulos G, Orsini E, Eilert RE. Autologous transfusions for orthopaedic procedures at a children's hospital. J Bone Joint Surg Am 1992;74(5):652-8.
62. Singbartl G. Adverse effects of erythropoietin in long-term and in acute/short-term treatment. Clin Invest 1994;72(6S):36S-43S.
63. Spence RK, Sculco TP, Keating EM, Nelson CL. Changing transfusion practices in orthopaedic surgery. Orthopedics 1995;18(9): 842-5.
64. Spence RK. Surgical red blood cell transfusion practice policies. Am J Surg 1995;170(6A):3S-10S.
65. Spivak L. The clinical physiology of erythropoietin. Semin Hematol 1993;30(4S):2-11.
66. Strauss RG. Erythropoietin in the pathogenesis and treatment of neonatal anemia. Transfusion 1995;35(1):68-73.
67. Thompson FL, Powers JS, Graber SE, Krantz SB. Use of recombinant human erythropoietin to enhance autologous blood donations in a patient with multiple red cell allo-antibodies and the anemia of chronic disease. Am J Med 1991;90:398-400.
68. Von Bormann B, Weiler J, Aulich S. Acute treatment with recombinant erythropoietin in patients with pre- and postoperative anemia: a clinical report. Clin Invest 1994;72(6S):31S-5S.
69. Willett DE. Legal aspects of blood transfusion. J Fla Med Assoc 1993;80(1):25-8.
70. Wylie BR. Transfusion transmitted infection: viral and exotic diseases. Anaesth Intensive Care 1993;21(1):24-30.
71. Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993;81(9):2223-36.